Treatment outcomes of curative radiotherapy in patients with vulvar cancer: Results of the retrospective KROG 1203 study

Youngkyong Kim, Joo Young Kim, Ja Young Kim, Nam Kwon Lee, Jin Hee Kim, Yong Bae Kim, Young Seok Kim, Juree Kim, Yeon Sil Kim, Dae-Sik Yang, Yeon Joo Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: We evaluated the prognostic factors and clinical outcomes of 56 patients with vulvar cancer treated with curative radiotherapy (RT) or concurrent chemoradiotherapy. Materials and Methods: Overall survival (OS) and disease-free survival (DFS) were assessed retrospectively. Prognostic factors evaluated included age, International Federation of Gynecology and Obstetrics (FIGO) stage, TNM classification, tumor size, treatment modality, RT duration, and RT field. The association between the tumor human papillomavirus (HPV) status and survival was analyzed in 35 patients. Results: During the median follow-up of 2.8 years (range, 0.3 to 18.9 years), 21 patients (37.5%) experienced treatment failure. Fifteen patients (27%) had local failure: nine (16%) local failure only, three (5%) locoregional failure, two (4%) local and distant failure, and one (2%) locoregional and distant failure. Of 56 patients, seven (13%) had persistent disease at the first follow-up at 2 months and all but one died within a year after completing RT. The 5-year OS and DFS were 51.6% and 44.0%, respectively. In multivariate analysis, clinical size ≥3 cm predicted a poor prognostic factor for DFS (p = 0.040) and age (≥70 years) was poor prognostic for DFS (p = 0.032) and OS (p = 0.048). Patients with HPV-positive tumors tended to have better 5-year OS and DFS, but the differences were not significant statistically. Conclusion: Clinical size ≥3 cm was a significant prognostic factor for DFS. However, age was the most important prognostic factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be considered for old age ≥70 years.

Original languageEnglish
Pages (from-to)198-206
Number of pages9
JournalRadiation Oncology Journal
Volume33
Issue number3
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Vulvar Neoplasms
Disease-Free Survival
Radiotherapy
Survival
Neoplasms
Neoplasm Staging
Chemoradiotherapy
Treatment Failure
Gynecology
Obstetrics
Multivariate Analysis
Therapeutics

Keywords

  • Radiotherapy
  • Risk factor
  • Survival
  • Vulvar cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Treatment outcomes of curative radiotherapy in patients with vulvar cancer : Results of the retrospective KROG 1203 study. / Kim, Youngkyong; Kim, Joo Young; Kim, Ja Young; Lee, Nam Kwon; Kim, Jin Hee; Kim, Yong Bae; Kim, Young Seok; Kim, Juree; Kim, Yeon Sil; Yang, Dae-Sik; Kim, Yeon Joo.

In: Radiation Oncology Journal, Vol. 33, No. 3, 01.01.2015, p. 198-206.

Research output: Contribution to journalArticle

Kim, Youngkyong ; Kim, Joo Young ; Kim, Ja Young ; Lee, Nam Kwon ; Kim, Jin Hee ; Kim, Yong Bae ; Kim, Young Seok ; Kim, Juree ; Kim, Yeon Sil ; Yang, Dae-Sik ; Kim, Yeon Joo. / Treatment outcomes of curative radiotherapy in patients with vulvar cancer : Results of the retrospective KROG 1203 study. In: Radiation Oncology Journal. 2015 ; Vol. 33, No. 3. pp. 198-206.
@article{0d576cfdfb964ccca961a55c8d319664,
title = "Treatment outcomes of curative radiotherapy in patients with vulvar cancer: Results of the retrospective KROG 1203 study",
abstract = "Purpose: We evaluated the prognostic factors and clinical outcomes of 56 patients with vulvar cancer treated with curative radiotherapy (RT) or concurrent chemoradiotherapy. Materials and Methods: Overall survival (OS) and disease-free survival (DFS) were assessed retrospectively. Prognostic factors evaluated included age, International Federation of Gynecology and Obstetrics (FIGO) stage, TNM classification, tumor size, treatment modality, RT duration, and RT field. The association between the tumor human papillomavirus (HPV) status and survival was analyzed in 35 patients. Results: During the median follow-up of 2.8 years (range, 0.3 to 18.9 years), 21 patients (37.5{\%}) experienced treatment failure. Fifteen patients (27{\%}) had local failure: nine (16{\%}) local failure only, three (5{\%}) locoregional failure, two (4{\%}) local and distant failure, and one (2{\%}) locoregional and distant failure. Of 56 patients, seven (13{\%}) had persistent disease at the first follow-up at 2 months and all but one died within a year after completing RT. The 5-year OS and DFS were 51.6{\%} and 44.0{\%}, respectively. In multivariate analysis, clinical size ≥3 cm predicted a poor prognostic factor for DFS (p = 0.040) and age (≥70 years) was poor prognostic for DFS (p = 0.032) and OS (p = 0.048). Patients with HPV-positive tumors tended to have better 5-year OS and DFS, but the differences were not significant statistically. Conclusion: Clinical size ≥3 cm was a significant prognostic factor for DFS. However, age was the most important prognostic factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be considered for old age ≥70 years.",
keywords = "Radiotherapy, Risk factor, Survival, Vulvar cancer",
author = "Youngkyong Kim and Kim, {Joo Young} and Kim, {Ja Young} and Lee, {Nam Kwon} and Kim, {Jin Hee} and Kim, {Yong Bae} and Kim, {Young Seok} and Juree Kim and Kim, {Yeon Sil} and Dae-Sik Yang and Kim, {Yeon Joo}",
year = "2015",
month = "1",
day = "1",
doi = "10.3857/roj.2015.33.3.198",
language = "English",
volume = "33",
pages = "198--206",
journal = "Radiation Oncology Journal",
issn = "2234-1900",
publisher = "Korean Society for Therapeutic Radiology and Oncology",
number = "3",

}

TY - JOUR

T1 - Treatment outcomes of curative radiotherapy in patients with vulvar cancer

T2 - Results of the retrospective KROG 1203 study

AU - Kim, Youngkyong

AU - Kim, Joo Young

AU - Kim, Ja Young

AU - Lee, Nam Kwon

AU - Kim, Jin Hee

AU - Kim, Yong Bae

AU - Kim, Young Seok

AU - Kim, Juree

AU - Kim, Yeon Sil

AU - Yang, Dae-Sik

AU - Kim, Yeon Joo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: We evaluated the prognostic factors and clinical outcomes of 56 patients with vulvar cancer treated with curative radiotherapy (RT) or concurrent chemoradiotherapy. Materials and Methods: Overall survival (OS) and disease-free survival (DFS) were assessed retrospectively. Prognostic factors evaluated included age, International Federation of Gynecology and Obstetrics (FIGO) stage, TNM classification, tumor size, treatment modality, RT duration, and RT field. The association between the tumor human papillomavirus (HPV) status and survival was analyzed in 35 patients. Results: During the median follow-up of 2.8 years (range, 0.3 to 18.9 years), 21 patients (37.5%) experienced treatment failure. Fifteen patients (27%) had local failure: nine (16%) local failure only, three (5%) locoregional failure, two (4%) local and distant failure, and one (2%) locoregional and distant failure. Of 56 patients, seven (13%) had persistent disease at the first follow-up at 2 months and all but one died within a year after completing RT. The 5-year OS and DFS were 51.6% and 44.0%, respectively. In multivariate analysis, clinical size ≥3 cm predicted a poor prognostic factor for DFS (p = 0.040) and age (≥70 years) was poor prognostic for DFS (p = 0.032) and OS (p = 0.048). Patients with HPV-positive tumors tended to have better 5-year OS and DFS, but the differences were not significant statistically. Conclusion: Clinical size ≥3 cm was a significant prognostic factor for DFS. However, age was the most important prognostic factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be considered for old age ≥70 years.

AB - Purpose: We evaluated the prognostic factors and clinical outcomes of 56 patients with vulvar cancer treated with curative radiotherapy (RT) or concurrent chemoradiotherapy. Materials and Methods: Overall survival (OS) and disease-free survival (DFS) were assessed retrospectively. Prognostic factors evaluated included age, International Federation of Gynecology and Obstetrics (FIGO) stage, TNM classification, tumor size, treatment modality, RT duration, and RT field. The association between the tumor human papillomavirus (HPV) status and survival was analyzed in 35 patients. Results: During the median follow-up of 2.8 years (range, 0.3 to 18.9 years), 21 patients (37.5%) experienced treatment failure. Fifteen patients (27%) had local failure: nine (16%) local failure only, three (5%) locoregional failure, two (4%) local and distant failure, and one (2%) locoregional and distant failure. Of 56 patients, seven (13%) had persistent disease at the first follow-up at 2 months and all but one died within a year after completing RT. The 5-year OS and DFS were 51.6% and 44.0%, respectively. In multivariate analysis, clinical size ≥3 cm predicted a poor prognostic factor for DFS (p = 0.040) and age (≥70 years) was poor prognostic for DFS (p = 0.032) and OS (p = 0.048). Patients with HPV-positive tumors tended to have better 5-year OS and DFS, but the differences were not significant statistically. Conclusion: Clinical size ≥3 cm was a significant prognostic factor for DFS. However, age was the most important prognostic factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be considered for old age ≥70 years.

KW - Radiotherapy

KW - Risk factor

KW - Survival

KW - Vulvar cancer

UR - http://www.scopus.com/inward/record.url?scp=84944074784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944074784&partnerID=8YFLogxK

U2 - 10.3857/roj.2015.33.3.198

DO - 10.3857/roj.2015.33.3.198

M3 - Article

AN - SCOPUS:84944074784

VL - 33

SP - 198

EP - 206

JO - Radiation Oncology Journal

JF - Radiation Oncology Journal

SN - 2234-1900

IS - 3

ER -